Celladon Corp.
2223 Avenida de la Playa
#300
La Jolla
CA
92037
USA
(858) 366-4288
(858) 964-0974
[email protected]
http://www.celladon.net
Product Categories
Stem Cell Therapies

Related Content

CUPID 2, gene transfer therapy, heart failure patients, no benefit, ESC 2015, SERCA2a
News | Stem Cell Therapies
No Benefit to Gene Transfer Therapy for Heart Failure Patients

September 4, 2015 — Gene transfer therapy to correct an enzyme abnormality involved in myocardial contraction and ...

Home September 04, 2015
arrow
MYDICAR Celladon Corp. Clinical Trial Heart Failure Treatments LVADs
News
Celladon Announces Initiation of Clinical Trial to Investigate MYDICAR in Patients With Heart Failure and a LVAD

August 13, 2014 — Celladon Corp. announced that the first patient has been dosed in a clinical trial titled ...

Home August 13, 2014
arrow
News
Celladon Receives FDA Breakthrough Therapy Designation for Novel Therapy in Development to Treat Heart Failure

April 30, 2014 — Celladon Corp. announced its lead product candidate, Mydicar, has been granted breakthrough therapy ...

Home April 30, 2014
arrow
News
Celladon Completes $43 Million Financing to Advance Mydicar for the Treatment of Heart Failure

February 20, 2012 — Biopharmaceutical company Celladon Corp. this week completed a $43 million equity financing to ...

Home February 20, 2012
arrow
News
Data Shared on First-In-Human Trial for Percutaneous Gene Therapy for Heart Failure

May 29, 2009 - Celladon Corp. this week presented phase 1 data from the Calcium Up-Regulation by Percutaneous ...

Home May 29, 2009
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now